Back to search results

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Biliary Tract Cancer · Metastatic Biliary Tract Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Olivia Aranha, M.D., Ph.D.) · oaranha@wustl.edu · 314-747-7509
    Contact: Principal Investigator (Olivia Aranha, M.D., Ph.D.)
    Kian-Huat Lim, M.D., Ph.D. (Sub-investigator)
    Greg Fox, M.D., Ph.D. (Sub-investigator)
    YiFei Xu, Ph.D. (Sub-investigator)
    Esther Lu, Ph.D. (Sub-investigator)
    Vivian Ortiz, M.D. (Sub-investigator)
Study leads

  • Olivia Aranha, M.D., Ph.D.

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)